Inactive

AMENDMENT THREE The purpose of Amendment Three is to: 1. Provide a cut-off date for submission of questions; 2. Provide a new deadline for proposal submissions to eCPS; 3. Provide an updated SBCX (sma... AMENDMENT THREE The purpose of Amendment Three is to: 1. Provide a cut-off date for submission of questions; 2. Provide a new deadline for proposal submissions to eCPS; 3. Provide an updated SBCX (small business subcontract plans) link; and 4. Respond to questions received regarding this solicitation. ______________________________________________________________________ AMENDMENT TWO The purpose of Amendment Two is to: 1. Respond to questions received regarding this solicitation. ______________________________________________________________________ AMENDMENT ONE The purpose of Amendment One is to: 1. Provide a cut-off date for submission of questions; 2. Provide updated instructions for the Proposal Intent Response Sheet; 3. Clarify submission instructions to eCPS; and 4. Respond to questions received regarding this solicitation. ______________________________________________________________________ Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has a requirement to support in vitro testing assess the therapeutic potential of compounds to advance our understanding of infectious diseases as well as advance the development of therapeutics for infectious diseases. Description NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts. The current solicitation addresses a critical stage in this pipeline by providing an efficient means to assess the therapeutic potential of compounds through in vitro testing. The overarching goal of the In Vitro Assessments of Antimicrobial Activity program is to provide capability in a broad range of in vitro testing capabilities to assess promising candidate countermeasures against the more than 270 infectious agents and vectors that are within the purview of DMID. In addition to meeting the needs of extramural researchers, it is anticipated that contracts resulting from this solicitation will provide crucial data to be used by NIAID partners at other agencies within the Department of Health and Human Services. Such data will facilitate the advancement of promising candidate medical countermeasures against priority emerging and bioterror infectious agents to approval or licensure and, in some cases, eventual deposit in the Strategic National Stockpile. In 2019, fourteen (14) institutions were awarded base contracts under the In Vitro Assessments of Antimicrobial Activity IDIQ contract program. Its overarching goal was to provide broad capability in in vitro methods to evaluate activity of candidate countermeasures against the full range of infectious agents in the purview of DMID. The breadth of the existing contractor pool has enabled a rapid and effective response to emerging threats such as SARS-CoV-2 and other emergency preparedness priorities. NIAID anticipates awarding multiple Indefinite Delivery, Indefinite Quantity (IDIQ) contracts to organizations that have the capabilities required to fulfill the technical requirements of the Task Areas described below. Offerors may submit to multiple Task Areas where they are capable to best meet the overall Task Area requirements, however, they must submit separate proposals for each of these Task Areas. Offerors will be considered for contracts only in the Task Area(s) included in their proposal(s), and successful Contractors may compete for task orders only in the Task Area(s) in which they are selected for award. Sample Task Orders will be provided in the Request for Proposal (RFP) solely to evaluate Offeror responses and capabilities. The Task Areas of this solicitation are as follows: Task Area A – Bacteria, Fungi, and Toxins Task Area B – Viruses Task Area C – Parasites and Vectors Task Area D – New Techniques to Culture Difficult-to-Grow Pathogens The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise, or facilities required to perform all activities set forth in the Statement of Work. Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through subcontracts, partnership or consortia agreements, and/or use of consultants. However, Contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management, and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order. Any responsible offeror may submit a proposal that will be considered by the Agency. This RFP will be available electronically on/about December 30, 2024, and may be accessed through SAM.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov and then click on "How to Submit." Follow the "How to Submit an Electronic Proposal" instructions provided on the eCPS website at: https://ecps.nih.gov/home/howto. Please note that creating an account to submit may take up to three (3) business days. Please apply for a new account early to allow enough time for the registration process.

Inactive

Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to ... Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has a requirement to support in vitro testing assess the therapeutic potential of compounds to advance our understanding of infectious diseases as well as advance the development of therapeutics for infectious diseases. Description NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts. The current solicitation addresses a critical stage in this pipeline by providing an efficient means to assess the therapeutic potential of compounds through in vitro testing. The overarching goal of the In Vitro Assessments of Antimicrobial Activity program is to provide capability in a broad range of in vitro testing capabilities to assess promising candidate countermeasures against the more than 270 infectious agents and vectors that are within the purview of DMID. In addition to meeting the needs of extramural researchers, it is anticipated that contracts resulting from this solicitation will provide crucial data to be used by NIAID partners at other agencies within the Department of Health and Human Services. Such data will facilitate the advancement of promising candidate medical countermeasures against priority emerging and bioterror infectious agents to approval or licensure and, in some cases, eventual deposit in the Strategic National Stockpile. In 2019, fourteen (14) institutions were awarded base contracts under the In Vitro Assessments of Antimicrobial Activity IDIQ contract program. Its overarching goal was to provide broad capability in in vitro methods to evaluate activity of candidate countermeasures against the full range of infectious agents in the purview of DMID. The breadth of the existing contractor pool has enabled a rapid and effective response to emerging threats such as SARS-CoV-2 and other emergency preparedness priorities. NIAID anticipates awarding multiple Indefinite Delivery, Indefinite Quantity (IDIQ) contracts to organizations that have the capabilities required to fulfill the technical requirements of the Task Areas described below. Offerors may submit to multiple Task Areas where they are capable to best meet the overall Task Area requirements, however, they must submit separate proposals for each of these Task Areas. Offerors will be considered for contracts only in the Task Area(s) included in their proposal(s), and successful Contractors may compete for task orders only in the Task Area(s) in which they are selected for award. Sample Task Orders will be provided in the Request for Proposal (RFP) solely to evaluate Offeror responses and capabilities. The Task Areas of this solicitation are as follows: Task Area A – Bacteria, Fungi, and Toxins Task Area B – Viruses Task Area C – Parasites and Vectors Task Area D – New Techniques to Culture Difficult-to-Grow Pathogens The NIAID recognizes that a single organization or institution may not have the full spectrum of expertise, or facilities required to perform all activities set forth in the Statement of Work. Contractors may need to be supported to a certain extent by the expertise and resources of other organizations or persons through subcontracts, partnership or consortia agreements, and/or use of consultants. However, Contractors shall be responsible for ALL work performed and shall be responsible for project planning, initiation, implementation, management, and communication; evaluation, selection, and management of subcontractors; and for all deliverables specified in this contract and each awarded Task Order. Any responsible offeror may submit a proposal that will be considered by the Agency. This RFP will be available electronically on/about December 30, 2024, and may be accessed through SAM.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov and then click on "How to Submit."

Inactive

Introduction This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding:... Introduction This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. Background The National Institute of Allergy and Infectious Diseases (NIAID) supports and facilitates research that focuses on understanding, treating and, ultimately, preventing infectious, immunologic, and allergenic diseases that threaten the lives of millions of people. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports and facilitates research to understand, control and prevent human disease caused by infectious agents. Basic, applied, and translational research to develop and assess therapeutics, vaccines, and diagnostics are supported through research grants, cooperative agreements, and contracts. In turn, DMID supports and facilitates these funding mechanisms via an array of resources and services. These programs include bioinformatics, structural biology, biorepositories, biocontainment facilities, and pre-clinical and clinical translational research resources. https://www.niaid.nih.gov/research/product-development-services In 2019, fourteen (14) institutions were awarded base contracts under the In Vitro Assessments of Antimicrobial Activity (IVAAA) Indefinite-Delivery / Indefinite-Quantity (IDIQ) contract program. Its overarching goal was to provide broad capability in in vitro methods to evaluate activity of candidate countermeasures against the full range of infectious agents in the purview of DMID. The breadth of the existing contractor pool has enabled a rapid and effective response to emerging threats such as SARS-CoV-2 and other emergency preparedness priorities. The current IDIQ contract program has supported the evaluation of hundreds of candidate countermeasures against bacteria, fungi, and viruses. As such, in response to requests from extramural investigators for early-stage testing of their products, these contracts facilitated critical go/no-go decisions and provided data that permitted advancement of promising countermeasures into further preclinical testing. Purpose and Objectives NIAID supports nearly all stages of the product development pipeline from in vitro therapeutic evaluation through advanced therapeutic and vaccine testing and manufacturing using multiple support services contracts. The anticipated solicitation addresses a critical stage in this pipeline by providing an efficient means to assess the therapeutic potential of compounds through in vitro testing. The overarching goal of the IVAAA program is to provide capability in a broad range of in vitro testing capabilities to assess promising candidate countermeasures against the more than 270 infectious agents and vectors that are within the purview of DMID. In addition to meeting the needs of extramural researchers, it is anticipated that contracts resulting from this solicitation will provide crucial data to be used by NIAID partners at other agencies within the Department of Health and Human Services. Such data will facilitate the advancement of promising candidate medical countermeasures against priority emerging and bioterror infectious agents to approval or licensure and, in some cases, eventual deposit in the Strategic National Stockpile. NIAID anticipates awarding IDIQ contracts to organizations that have the capabilities required to fulfill the technical requirements of the Task Areas of the anticipated solicitation. Offerors will be considered for contracts only in the Task Area(s) included in their proposal(s), and successful Contractors may compete for task orders only in the Task Area(s) in which they are selected for award. The Task Areas of the anticipated solicitation are as follows: Task Area A – Bacteria, Fungi, and Toxins Task Area B – Viruses Task Area C – Parasites and Vectors Task Area D – New Techniques to Culture Difficult-to-Grow Pathogens Project requirements This requirement will enable DMID to provide a broad and flexible range of in vitro assay capabilities for human infectious diseases or diseases of human importance caused by infectious agents, including but not limited to product screening, assay development, and development of improved systems for in vitro culturing of difficult-to-grow pathogens. These capabilities will allow the NIAID to respond to changing priorities as scientific and public health needs shift, including rapid responses to public health emergencies. NOTE: In vitro assessments of antimicrobial activity against pathogens, vectors or toxins which only cause disease in animals are not supported, unless these pathogen/animal systems are models for human disease. For the purposes of this solicitation the following definitions apply: Assays – in vitro procedures for determining biological activity of a substance by measuring its effect on an organism, tissue, cell, enzyme or receptor preparation. In addition, in vitro procedures for determining the concentration, and/or purity of a substance. Products – broadly defined and include therapeutic substances targeting the host or the pathogen (May be used interchangeably with test article). Pathogens – bacteria, viruses, parasites, and fungi. Toxins –products of microbial origin that induce a pathological effect in a host, but are not the microbe itself. Vectors – arthropods (usually insects) or mollusks that carry pathogens from infected to uninfected hosts. Reagents – biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens, toxins, and vectors. Anticipated period of performance It is anticipated that multiple award IDIQ contracts will be awarded with a seven-year ordering period. Capability statement/information sought Capability Statements should clearly convey information regarding the respondent’s capabilities including: (1) staff expertise, including their availability, experience, and formal and other training; (2) current in-house capability and capacity to perform the work; (3) prior completed projects of similar nature; and (4) institutional/corporate experience and management capability. Interested respondents must submit a capability statement describing their company’s experience and ability to perform this effort that includes the following: • A summary list of similar work previously performed; • The professional qualifications and specific experience of staff who may be assigned to the requirement; • Resumes for proposed key personnel, including the Principal Investigator, that reflect education, and previous work relevant to the proposed requirement; • Documented adequacy, appropriateness and relevance of expertise, experience, qualifications, and availability of the key professional and technical staff with a project of similar size, scope, and complexity; • Documented adequacy and appropriateness of proposed organization and staffing to ensure efficient planning, initiation, implementation, conduct, and completion of all activities, including plans for communication and sharing of research resources; • A general description of the facilities and other resources necessary to conduct work with hazardous biological materials in compliance with all Federal and NIH regulations in accordance with current Biosafety in Microbiological and Biomedical Laboratories (BMBL), guidelines available at: https://www.cdc.gov/labs/pdf/SF__19_308133-A_BMBL6_00-BOOK-WEB-final-3.pdf, and where applicable, compliant with the Select Agent Regulations through the Centers for Disease Control (CDC) and/or the United States Department of Agriculture (USDA) (42 CFR Part 73, 7 CFR Part 331, and/or 9 CFR Part 121[VM([2] ). • Demonstrated ability to carry out the work; • Adequacy of the documented experience with, and appropriateness of plans for the general technical approach to product screening, assay development, and development of improved systems for culturing difficult to grow pathogens in vitro. Page Limitations: Interested qualified small business organizations should submit a tailored Capability Statement not to exceed five (5) pages, excluding resumes. Capability Statements must not include links to internet web site addresses (URLs) or otherwise direct readers to alternate sources of information. Font size must be 10 to 12 points. Spacing must be no more than 15 characters per inch. Within a vertical inch, there must be no more than six lines of text. Print margins must be at least one inch on each edge of the paper. Print setup should be single sided on standard letter size paper (8.5 x 11" in the U.S., A4 in Europe). All proprietary information should be marked as such. Required Business Information: Unique Entity ID Company Name Company Address Company Point of Contact, Phone and Email address Current GSA Schedules and/or Government-wide Acquisition Contracts (GWACs) appropriate to this Sources Sought. Do you have a Government approved accounting system? If so, please identify the agency that approved the system. Type of Company (i.e., small business, 8(a), woman owned, veteran owned, etc.) as validated via the System for Award Management (SAM) located at https://sam.gov/content/home. This indication should be clearly marked on the first page of your Capability Statement (preferable placed under the eligible small business concern’s name and address). Number of Copies: Please submit one (1) electric copy of your response as follows: All Capability Statements sent in response to this Small Business Sources Sought notice must be submitted electronically (via e-mail) to Alexander Beraud, Contract Specialist, at alexander.beraud@nih.gov in MS Word or Adobe Portable Document Format (PDF). The email subject line must specify "75N93024R00024 Small Business Sources Sought" . Facsimile responses will not be accepted. Common Cut-off Date: Electronically submitted tailored capability statements are due no later than 3:00 PM (EDT) on August 14, 2024. CAPABILITY STATEMENTS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED. Disclaimer and Important Notes This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published at SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).”